Bioventus (NASDAQ:BVS) Posts Earnings Results, Meets Estimates

by · The Markets Daily

Bioventus (NASDAQ:BVS – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.22 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.22, FiscalAI reports. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The business had revenue of $153.21 million for the quarter. Bioventus updated its FY 2026 guidance to 0.750-0.790 EPS.

Here are the key takeaways from Bioventus’ conference call:

  • Positive Sentiment: Bioventus reported second-quarter revenue of $153 million, up 4% year over year, with Pain Treatments revenue rising 12% to $82 million, led by double-digit volume growth in DUROLANE.
  • Positive Sentiment: The company reaffirmed its 2026 guidance for revenue of $600 million–$610 million, adjusted EPS of $0.75–$0.79, and operating cash flow of $84 million–$89 million, while expecting stronger growth in the second half.
  • Positive Sentiment: Management cited encouraging adoption indicators for PRP, PNS, and Ultrasonics, including accelerating capital placements, disposable reorders, trial-to-implant conversions, and new large-account wins. It plans to increase investment in these growth drivers, particularly PNS, in the second half.
  • Positive Sentiment: Adjusted EBITDA margin expanded to 23%, adjusted EPS increased to $0.22, and the company repaid $24 million of debt during the quarter. Net leverage fell below 2x, with management targeting below 1.5x by year-end.
  • Neutral Sentiment: The board launched a strategic review after receiving multiple expressions of interest and an unsolicited acquisition proposal, with options including a potential sale or continued standalone execution. Management provided no further details on timing or valuation.

Bioventus Stock Performance

BVS traded up $1.70 during trading on Wednesday, reaching $15.12. 1,779,028 shares of the company’s stock were exchanged, compared to its average volume of 517,458. The company has a market capitalization of $1.26 billion, a P/E ratio of 36.87, a PEG ratio of 1.72 and a beta of 0.63. The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08. The business has a 50 day moving average price of $10.47 and a 200 day moving average price of $9.56. Bioventus has a fifty-two week low of $6.26 and a fifty-two week high of $15.89.

Institutional Trading of Bioventus

Several institutional investors have recently made changes to their positions in the business. Engine Capital Management LP acquired a new stake in Bioventus during the first quarter valued at approximately $2,876,000. Hillsdale Investment Management Inc. lifted its holdings in shares of Bioventus by 148.7% during the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after acquiring an additional 401,230 shares during the period. Fifth Third Bancorp bought a new position in shares of Bioventus during the first quarter valued at $1,478,000. Wesbanco Bank Inc. acquired a new stake in shares of Bioventus in the 1st quarter valued at $895,000. Finally, Legato Capital Management LLC boosted its stake in shares of Bioventus by 1,042.8% in the 4th quarter. Legato Capital Management LLC now owns 137,562 shares of the company’s stock valued at $1,023,000 after purchasing an additional 125,525 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BVS. Barrington Research reiterated an “outperform” rating and issued a $14.00 target price on shares of Bioventus in a research note on Tuesday, June 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of Bioventus in a report on Tuesday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Bioventus has an average rating of “Buy” and an average price target of $14.75.

Get Our Latest Research Report on Bioventus

About Bioventus

(Get Free Report)

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

Read More